<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04232813</url>
  </required_header>
  <id_info>
    <org_study_id>IP-AVV2019</org_study_id>
    <nct_id>NCT04232813</nct_id>
  </id_info>
  <brief_title>Evaluation of the Acceptability and Efficacy of 10 Micrograms of Estradiol Vaginal Tablets vs Promestriene Vaginal Cream</brief_title>
  <official_title>Evaluation of the Acceptability and Efficacy of 10 Micrograms of Estradiol Vaginal Tablets vs Promestriene Vaginal Cream</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Palacios</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Palacios</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the Acceptability and Efficacy of 10 Micrograms of Estradiol Vaginal Tablets vs
      Promestriene Vaginal Cream in postmenopausal women aged 45 years or older, with one or more
      moderate to severe symptoms of vulvovaginal atrophy (dryness, dyspareunia, soreness or
      irritation).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 9, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A Prospective, monocentric, open-label, randomized, parallel-group study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vulvovaginal Symptoms</measure>
    <time_frame>Change from Baseline, at week 4 and at week 12</time_frame>
    <description>Percentage of patients with vulvovaginal atrophy that accept 17B-Estradiol vaginal tablets vs promestriene vaginal cream after 12 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of relief of atrophic vaginitis symptoms using intensity ratings of none, mild, moderate or severe of dryness and dyspareunia.</measure>
    <time_frame>Change from Baseline, at week 4 and at week 12</time_frame>
    <description>Percentage of women that verify a relief of atrophic vaginitis dryness, dyspareunia, soreness and irritation symptoms in the questionnaires provided at Visit 1 and Visit 2 compared to intensity of those symptoms at screening visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of changes in ph.</measure>
    <time_frame>Change from Baseline, at week 4 and at week 12</time_frame>
    <description>Percentage of women with changes in pH at Visit 1 and Visit 2 compared to Screening Visit. Comparison with the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of vaginal maturation index by Pap smear.</measure>
    <time_frame>Change from Baseline, at week 4 and at week 12</time_frame>
    <description>Percentage of woman with changes in vaginal maturation index by Pap smear at Visit 2 compared to Screening Pap smear and comparison between groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of changes in soreness and irritation.</measure>
    <time_frame>Change from Baseline, at week 4 and at week 12</time_frame>
    <description>Percentage of women that verify a relief of atrophic vaginitis dryness, dyspareunia, soreness and irritation symptoms in the questionnaires provided at Visit 1 and Visit 2 compared to intensity of those symptoms at screening visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>Change from Baseline, at week 4 and at week 12</time_frame>
    <description>Number of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of endometrium thickness using vaginal ultrasound</measure>
    <time_frame>Change from Baseline, at week 4 and at week 12</time_frame>
    <description>Percentage of women with changes in endometrium thickness at Visit 2 compared to Screening Visit and comparison between groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Vulvovaginal Atrophy</condition>
  <arm_group>
    <arm_group_label>Estradiol 10 micrograms vaginal tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One tablet intravaginally once daily for two weeks. Thereafter one tablet twice per week with at least a 3-days interval between treatments to maintain therapeutic response.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Promestriene 10mg./g vaginal cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One application once daily intravaginally for two weeks. Thereafter one application twice per week with at least a 3-days interval between treatments to maintain therapeutic response.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol 10 MCG Vaginal Tablet [VAGIFEM]</intervention_name>
    <description>To insert the tablets the patient must use the applicator provided in the way explained in the prospectus.</description>
    <arm_group_label>Estradiol 10 micrograms vaginal tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Promestriene Vaginal</intervention_name>
    <description>To insert the cream the patient must use the applicator provided in the way explained in the prospectus.</description>
    <arm_group_label>Promestriene 10mg./g vaginal cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women aged 45 years or older. Women will be considered postmenopausal
             with more than 12 months since last menstrual period

          -  Women who have read and signed the Informed Consent Form

          -  Women with an intact uterus

          -  One or more vaginal symptoms (dryness, soreness, irritation, dyspareunia) rated as
             moderate to severe. Symptoms are moderate if the patient needs a treatment and feels
             discomfort. Symptoms are severe if the patient needs a treatment, and feels such a
             degree of discomfort that this could severely impact the subject's daily activities.

          -  Blood estradiol concentration of 30 pg/ml or less .

        Exclusion Criteria:

          -  Women who have not signed the Informed consent Form

          -  Women who had a known or suspected history of breast carcinoma

          -  Estrogen dependent neoplasia. Women with a known, past or suspected Estrogen-dependent
             malignant tumours such as endometrial or ovarian cancer

          -  Positive or suspicious mammogram results

          -  Any systemic malignant disease

          -  Hormone therapy treatment (sex hormones or vaginal treatments or steroids) in the last
             three months

          -  Women who had abnormal vaginal bleeding or uterine bleeding of unknown cause

          -  Vaginal infection requiring treatment

          -  Previous or current venous thromboembolism (deep venous thrombosis, pulmonary
             embolism) Untreated endometrial hyperplasia Known thrombophilic disorders (e.g.
             protein C, protein S, or antithrombin deficiency) Active or previous arterial
             thromboembolic disease (e.g. angina, myocardial infarction) Acute liver disease, or
             history of liver disease as long as liver function tests have failed to return to
             normal Known Hypersensitivity to the active substances or to any of the excipients
             Porphyria

          -  Any serious disease or chronic condition that could interfere with study compliance

          -  History of thrombolytic disorders

          -  Use of vaginal contraceptives (DIU, vaginal ring…)

          -  Participation in another clinical trial in the last three months.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr. Santiago Palacios</last_name>
    <phone>+34 91 578 05 17</phone>
    <email>ipalacios@institutopalacios.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dra. Marieta Ramírez</last_name>
    <phone>+34 91 578 05 17</phone>
    <email>investigacion@institutopalacios.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Palacios</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mónica González Sanz</last_name>
      <phone>+34 91 578 05 17</phone>
      <email>investigacion@institutopalacios.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 10, 2020</study_first_submitted>
  <study_first_submitted_qc>January 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaginal dryness</keyword>
  <keyword>Vaginal soreness</keyword>
  <keyword>Vaginal irritation</keyword>
  <keyword>Dyspareunia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

